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Angiotensin II: a major regulator of subcutaneous adipose
tissue blood flow in humans
G. H. Goossens1,2, S. E. McQuaid2, A. L. Dennis2, M. A. van Baak1, E. E. Blaak1, K. N. Frayn2,
W. H. M. Saris1 and F. Karpe2
1Department of Human Biology, Nutrition and Toxicology Research Institute Maastricht (NUTRIM), Maastricht University, Maastricht, The Netherlands
2Oxford Centre for Diabetes, Endocrinology and Metabolism, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK
We investigated the functional roles of circulating and locally produced angiotensin II (Ang II)
in fasting and postprandial adipose tissue blood flow (ATBF) regulation and examined the
interaction between Ang II and nitric oxide (NO) in ATBF regulation. Local effects of the
pharmacological agents (or contralateral saline) on ATBF, measured with 133Xe wash-out,
were assessed using the recently developed microinfusion technique. Fasting and postprandial
(75 g glucose challenge) ATBF regulation was investigated in nine lean healthy subjects (age,
29 ± 3 years; BMI, 23.4 ± 0.7 kg m−2) using local Ang II stimulation, Ang II type 1 (AT1)
receptor blockade, and angiotensin-converting enzyme (ACE) inhibition. Furthermore, NO
synthase (NOS) blockade alone and in combination with AT1 receptor blockade was used to
examine the interaction between Ang II and NO. Ang II induced a dose-dependent decrease in
ATBF (10−9 M: −16%, P = 0.04; 10−7 M: −33%, P< 0.01; 10−5 M: −53% P< 0.01). Fasting
ATBF was not affected by ACE inhibition, but was increased by ∼55% (P< 0.01) by AT1 receptor
blockade. NOS blockade induced a ∼30% (P = 0.001) decrease in fasting ATBF. Combined AT1
receptor and NOS blockade increased ATBF by ∼40% (P = 0.003). ACE inhibition and AT1
receptor blockade did not affect the postprandial increase in ATBF. We therefore conclude
that circulating Ang II is a major regulator of fasting ATBF, and a major proportion of the
Ang II-induced decrease in ATBF is NO independent. Locally produced Ang II does not appear
to regulate ATBF. Ang II appears to have no major effect on the postprandial enhancement of
ATBF.
(Resubmitted 4 November 2005; accepted after revision 4 January 2006; first published online 5 January 2006)
Corresponding author G. H. Goossens: Department of Human Biology, Nutrition and Toxicology Research Institute
Maastricht (NUTRIM), Maastricht University, Maastricht, The Netherlands. Email: g.goossens@hb.unimaas.nl
Tissue-specific regulation of blood flow in tissues such
as skeletal muscle, liver and adipose tissue is needed to
meet the local metabolic and physiological demands under
varying conditions. Previous studies have clearly shown
that adipose tissue blood flow (ATBF) is increased after
glucose intake (Bulow et al. 1987) or the ingestion of
a mixed meal (Coppack et al. 1992), whereas fat intake
alone does not evoke a blood flow response (Evans et al.
1999). The ATBF response to nutrient intake may be
of great importance in the regulation of metabolism by
facilitating signalling between adipose tissue and other
tissues, such as skeletal muscle and liver (Frayn et al. 2003).
For example, it has been shown that the extraction of
plasma triacylglycerol is elevated with increasing ATBF
(Samra et al. 1996b).
Both fasting ATBF (Blaak et al. 1995; Summers et al.
1996; Jansson et al. 1998) and ATBF responsiveness
to nutrients (Summers et al. 1996; Jansson et al.
1998) are reduced in obesity, and this impairment is
associated with insulin resistance (Jansson et al. 1998;
Karpe et al. 2002b). Although insulin itself does not
seem to be the actual stimulus for this nutrient-related
elevation of ATBF (Karpe et al. 2002a), it has been
demonstrated that the postprandial enhancement of ATBF
coincides with an increased plasma insulin concentration
and suppression of circulating non-esterified fatty acids
(NEFA) (Coppack et al. 1992). There is abundant evidence
that β-adrenergic stimulation elevates ATBF (Blaak et al.
1995; Samra et al. 1996a; Millet et al. 1998; Schiffelers
et al. 2003) and it has recently been shown that a major
proportion of the postprandial enhancement of ATBF
results from local β-adrenergic stimulation (Ardilouze
et al. 2004a), which may be secondary to the post-
prandial increase in insulin concentrations that might
activate the sympathetic nervous system (Karpe et al.
2002a). Furthermore, nitric oxide (NO) seems to be
involved in fasting ATBF regulation (Ardilouze et al.
2004a).
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There is evidence for a local angiotensin (Ang) II
generating system in adipose tissue (Dzau, 1988; Unger
& Gohlke, 1990; Phillips et al. 1993; Danser, 1996; Harte
et al. 2005), implying that the vasoactive component
Ang II may be produced in adipose tissue. Local Ang II
stimulation using the microdialysis technique decreased
fasting nutritive blood flow and inhibited lipolysis in
abdominal subcutaneous adipose tissue and skeletal
muscle in normal-weight and obese subjects (Goossens
et al. 2004). However, the functional importance of locally
produced Ang II in adipose tissue and circulating Ang II
and their role in postprandial ATBF regulation have never
been assessed. In addition, there is evidence that Ang II
increases oxidative stress and interacts with NO function,
leading to endothelial dysfunction (de Gasparo, 2002).
This suggests that there could be an interaction between
Ang II and NO in the Ang II-induced effect on ATBF.
Therefore, we used a pharmacological approach, using
local Ang II stimulation, Ang II type 1 (AT1) receptor
blockade, and ACE inhibition, to investigate whether
locally produced and circulating Ang II decrease ATBF
both under fasting and postprandial conditions. We also
examined the contribution of NO to the Ang II-induced
effect on ATBF using NO synthase (NOS) blockade. To
accomplish this, the recently developed microinfusion
technique was used, which makes quantitative assessment
of the local effects of vasoactive compounds on ATBF
possible (Karpe et al. 2002a). With the model used in
the present study, we are to our knowledge the first to
determine the relative contribution of locally produced
Ang II in adipose tissue and circulating Ang II that reaches
adipose tissue to an Ang II-induced effect in this tissue.
Methods
Subjects
Nine lean healthy non-smoking volunteers (5 female) free
of any medication participated in the studies. Subject
characteristics are summarized in Table 1. The micro-
infusion system allows for local administration of up
to two pharmacological agents simultaneously in the
same subject. Most participants participated in three of
the four experiments using different protocols. Subject
characteristics and distribution of the sexes did not differ
between experiments. The Oxfordshire Clinical Research
Ethics Committee approved the studies, which conformed
to the Declaration of Helsinki, and all subjects gave written
informed consent before participating in the studies.
Study design
Subjects were asked to refrain from drinking alcohol
and doing strenuous exercise for a period of 24 h
before the study. Subjects came to the Clinical Research
Table 1. Subject characteristics
Parameter Mean ± S.E.M.
Sex (male/female) 4/5
Age (years) 30 ± 3
Weight (kg) 70.1 ± 4.1
Height (m) 1.72 ± 0.04
BMI (kg m−2) 23.4 ± 0.7
Body fat (%) 22.7 ± 2.2
Waist (cm) 79.0 ± 2.1
Waist/hip ratio 0.82 ± 0.02
SBP (mmHg) 112 ± 4
DBP (mmHg) 67 ± 1
Fasting glucose (mmol l−1) 4.9 ± 0.1
Fasting insulin (mU l−1) 9.5 ± 0.5
BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic
blood pressure.
Unit by car or bus in the morning after an overnight
fast and were studied at rest. On arrival, height,
weight, waist and hip circumferences were measured.
Body composition was determined using bioelectrical
impedance (Bodystat-1500, Bodystat Ltd, Isle of Man,
UK).
Small catheters were inserted into the abdominal
subcutaneous adipose tissue (see ‘Microinfusion
protocol’). Resting blood pressure was recorded after
15 min rest and at intervals throughout the study.
A 20-gauge cannula was inserted retrogradely into a
superficial dorsal hand vein. This vein was heated in a
hot box for at least 20 min to obtain arterialized venous
blood. Arterialized blood samples were taken at different
time points, depending on the type of experiment.
Microinfusion protocol
The microinfusion technique offers the unique possibility
of monitoring local ATBF using the 133xenon (133Xe)
wash-out technique (Samra et al. 1995) and to manipulate
local ATBF at the same time by local administration of
a pharmacological agent (Karpe et al. 2002a). Right and
left sides of the abdomen were studied simultaneously on
each subject to allow direct comparison of the effects of the
vasoactive compound on one site with the contralateral
control site (saline infusion, 9 g l−1 NaCl). Importantly,
the vasoactive compound was administered at the same
level on the abdomen as the saline control site, as it
has been previously shown that ATBF is greater at the
upper level compared to the lower level of the abdomen
(Simonsen et al. 2003; Ardilouze et al. 2004b), but is not
different between the right and the left sides at either
level (Ardilouze et al. 2004b). To achieve this, small
catheters (6 mm long, internal diameter 0.38 mm, outer
diameter 1.5 mm, dead-space volume 60 μl) (Quick-set
infusion set, MiniMed, Applied Medical Technology Ltd,
C© 2006 The Authors. Journal compilation C© 2006 The Physiological Society
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Cambridge, UK) were inserted 6–8 cm on either side
of the midline of the abdomen into the abdominal
subcutaneous adipose tissue, and a saline infusion was
started at 2 μl min−1 (CMA100 pumps, CMA micro-
dialysis Ltd, Sunderland, UK). After 20 min recovery, 133Xe
(total dose of 2.0 MBq per study) was injected at each site
through the port in the hub of the catheter, and aγ -counter
probe (Oakfield Instruments, Eynsham, UK) was placed
over the infusion device. The half-life of 133Xe (5.25 days)
allows measurements of local ATBF throughout the entire
study after a single injection of 133Xe. Subsequently, the
catheter was perfused with saline for 1 min at 60 μl min−1
to wash the dead space, and for a further 40–60 min at
2 μl min−1 to allow for equilibration of 133Xe. Importantly,
it can be estimated that tissue concentrations of the
agents that are administered are approximately 1000-fold
lower than the concentrations in the infusate. Using the
present methodology (infusing agents at an infusion rate
of 2 μl min−1 in a presumed volume of 1 cm3), it would
take several hours to achieve tissue concentrations that
are comparable with the concentrations in the infusate. In
addition, there is a rapid turnover of the fluid phase due
to ATBF, which further dilutes the tissue concentrations.
Ang II dose–response experiments
The effect of angiotensin II (Ang II: 10−9, 10−7, 10−5 m) on
ATBF was investigated in four subjects (Fig. 1A). At time
zero, the saline was switched at either the left or the right
side (chosen at random), by disconnection at the hub of
the infusion set, to Ang II (h-Angiotensin II, Clinalfa, CH),
while the infusion rate was maintained at 2 μl min−1. Each
dose of Ang II was administered for 45 min starting with
the lowest dose. The ATBF recording over the next 135 min
assessed the effect of Ang II, while the saline infusion was
continued on the contralateral site to examine whether
there were any changes in ATBF during the experiment
that could not be attributed to Ang II action. After two
baseline arterialized blood samples had been taken at time
points (t, in minutes) −20 (t–20) and t0, further samples
were taken at t45, t90 and t135. Ang II was dissolved in
saline and diluted to the appropriate concentrations just
before the start of the experiment.
AT1 receptor blockade and ACE inhibition
experiments
The effects of the ACE inhibitor enalaprilate (10−3 m) and
the specific AT1 receptor antagonist losartan (10−3 m) were
investigated in six subjects to examine the importance
of locally produced and circulating Ang II in fasting and
postprandial ATBF regulation (Fig. 1B). The reason for
using a high dose of the ACE inhibitor was to block local
Ang II generation. Similarly, a high dose of the AT1 receptor
blocker was administered to block Ang II action.
At time zero, the saline was switched at either the
left or the right side (chosen at random) to either
the ACE inhibitor enalaprilate (Renitec, MSD, Haarlem,
The Netherlands) or the AT1 receptor blocker losartan
(Cozaar, MSD), while the infusion rate was maintained
at 2 μl min−1. The ATBF recording over the next 60 min
assessed the effects of ACE inhibition and AT1 receptor
blockade, while the saline infusions were continued on the
contralateral sites. At t60, 75 g glucose dissolved in 200 ml
of lemon-flavoured water was ingested to stimulate ATBF,
and infusions were continued for a further 120 min. After
two baseline arterialized blood samples had been taken
(at t–20 and t0), additional samples were taken at 30 min
intervals. Losartan was dissolved in saline, sterile-filtered
and diluted to the appropriate concentration just before
the start of the experiment. Enalaprilate was provided as a
sterile solution by the manufacturer.
Ang II–NO interaction experiments
To assess the contribution of NO action to the Ang II-
induced effect on ATBF, the effects of the NO synthase
(NOS) inhibitor N G-monomethyl-l-arginine (l-NMMA)
alone (10−3 m) and in combination with the AT1 receptor
blocker losartan (10−3 m) were investigated in five
subjects (Fig. 1C). At time zero, the saline was switched
at either the left or the right side (chosen at random) to
the NOS inhibitor l-NMMA, while the infusion rate was
maintained at 2 μl min−1. The ATBF recording over the
next 60 min assessed the effect of NOS blockade, while
the saline infusions were continued on the contralateral
sites. At t60, one of the saline sites (chosen at random)
was switched to the AT1 receptor blocker and one of the
NOS blockade sites was switched to the AT1 receptor
blocker in combination with the NOS inhibitor, and
infusions were continued for a further 60 min to assess the
interaction between Ang II and NO in ATBF regulation.
After two baseline arterialized blood samples had been
taken (at t–20 and t0), further samples were taken at t60
and t120. l-NMMA was dissolved in saline, sterile-filtered
and diluted to the appropriate concentration just before
the start of the experiment.
Biochemical measurements
Arterialized blood samples were immediately placed on
ice and were centrifuged (1000 g) at 4◦C for 10 min,
and plasma was stored at −20◦C until analysis. Plasma
glucose (Simonsen et al. 2003) and non-esterified fatty
acids (NEFA) concentrations (Wako NEFA C kit, Alpha
Laboratories, Eastleigh, UK) were measured using an
enzymatic method. Plasma insulin concentrations were
determined by a double-antibody radioimmunoassay
(Pharmacia and Upjohn, Milton Keynes, UK).
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Calculations
133Xe counts were recorded continuously as 20 s readings,
and blood flow was calculated as the mean of consecutive
10 min time periods, as previously described (Karpe et al.
Figure 1. Time line diagrams of the different experiments
Ang II dose–response experiments were performed to assess the effect of local Ang II stimulation on adipose tissue
blood flow (ATBF) (A). In addition, the functional ATBF response to the ACE inhibitor enalaprilate (inhibition of local
Ang II production) and the AT1 receptor blocker losartan (complete blockade of Ang II action) (B) was investigated
under fasting and postprandial (after 75 g oral glucose at 60 min (t60)) conditions. To assess the contribution of
NO action to the Ang II-induced effect on ATBF, the ATBF response to the NOS inhibitor L-NMMA (inhibition of local
NO production) in combination with AT1 receptor blockade was compared to the ATBF response to NOS blockade
alone (C). Thick arrows represent blood samples and blood pressure time points.
2002a; Ardilouze et al. 2004a). The partition coefficient
for 133Xe between adipose tissue and blood was assumed
to have a value of 10 g ml−1 for all subjects (Yeh & Peterson,
1965).
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The effect of Ang II was analysed by averaging the
two consecutive time points at the end of each 45 min
infusion period (t35 and t45, t80 and t90, and t125 and
t135), when a steady state in ATBF was reached, after
subtraction of baseline blood flow (t–20 to t0). It is
important to recognize that we cannot be certain of the
volume of distribution of the agents infused with respect
to the depot of 133Xe and the exact tissue concentrations,
because microinfusion of pharmacological agents creates
drug concentration gradients in the tissue volume from
which 133Xe clearance is recorded. This experimental
problem implies that the estimates of the size of the effects
of the pharmacological agents that are infused on ATBF
should be regarded as qualitative or semi-quantitative.
For the AT1 receptor blockade and ACE inhibition
experiments, the stability of ATBF during the base-
line period (t–20 to t0) and the 30 min period before
glucose ingestion (pre-glucose period, t30 to t60) at the
control (saline) sites was tested using Student’s paired
t test. Responses to pharmacological agents were evaluated
within individuals by comparison with the saline control
site at the same level on the abdomen. Relative changes
in ATBF at the experimental site are presented as changes
from baseline values after correction for corresponding
changes in ATBF at the control site. The effects of local AT1
receptor blockade and ACE inhibition were analysed by
averaging the three consecutive time points before glucose
intake (t40, t50 and t60) after subtraction of baseline
blood flow (t–20 to t0). Peak ATBF values were calculated
as the mean of three consecutive time points, including
the maximum ATBF, which resulted in the highest mean
value within each subject (Karpe et al. 2002a). The effect
of glucose intake on ATBF was analysed using the area
under the curve (AUC) by the trapezoidal rule. AUCs
were divided by the time over which they were calculated
(120 min). To assess the contribution of NO action to the
Ang II-induced effect on ATBF, the effect of combined AT1
receptor and NOS blockade was compared with that of AT1
receptor blockade alone by averaging the three consecutive
time points at the end of each 60 min infusion period (t40,
t50 and t60, and t100, t110 and t120). The reproducibility
of the blood flow recordings was assessed by calculating
coefficients of variation (CVs).
Statistics
Data are presented as mean ± standard error of the
mean (s.e.m.). Overall effects of treatment compared
with control were analysed using repeated-measures
ANOVA to identify time effects, drug effects, and
time and drug interactions. Changes in glucose, insulin
and NEFA concentrations with time were assessed by
repeated-measures ANOVA, using time and treatment as
within-subject factors.Post hoc comparisons of drug effects
and changes in biochemical data within subjects were done
using Student’s paired t tests. Calculations were done using
SPSS 10.1 for Windows (Chicago, IL, USA). P < 0.05 was
considered to be statistically significant.
Results
Systemic responses
Fasting plasma glucose (4.9 ± 0.1 mmol l−1), insulin
(9.5 ± 0.5 mU l−1), and NEFA (551 ± 72 μmol l−1)
concentrations were stable during the baseline period and
the 30 min period before glucose ingestion (pre-glucose
period) in the AT1 receptor blockade and ACE inhibition
experiments and during the course of the Ang II
dose–response and Ang II–NO interaction experiments.
After ingestion of glucose in the AT1 receptor blockade
and ACE inhibition experiments, plasma glucose and
insulin concentrations were significantly increased,
whereas plasma NEFA concentrations were significantly
decreased. Concentrations and responses corresponded
to those expected in healthy lean subjects and were
comparable between the different experiments. Mean
blood pressure was unchanged during the course of the
experiments (data not shown).
Reproducibility of blood flow recordings
Baseline blood flow recordings were stable; there were
no significant differences in ATBF between t–20 and t0
in the different experiments: mean values were 5.0 ± 0.4
and 5.1 ± 0.4 ml (100 g tissue)−1 min−1, respectively (CV,
5.8 ± 0.8%). Baseline ATBF was significantly correlated
between right and left sides (Pearson’s r = 0.89, P < 0.001
and r = 0.92, P < 0.001 for superior and inferior sides,
respectively). The CVs, calculated from the paired
data from left and right sides, were 18.8 ± 1.9% and
15.9 ± 4.7% for superior and inferior sides, respectively.
Effect of Ang II on ATBF
Ang II stimulation induced a dose-dependent decrease in
ATBF (10−9 m: −16%, P = 0.04; 10−7 m: −33%, P < 0.01;
10−5 m: −53%, P < 0.01 compared to baseline) (Fig. 2).
The reduction in ATBF during Ang II stimulation
was significantly different between the different Ang II
concentrations that were administered (10−9 m versus
10−7 m, P = 0.03; 10−7 m versus 10−5 m, P < 0.01). As
expected, saline infusion on the contralateral site had no
effect on ATBF, indicating that the effect of local Ang II
stimulation on ATBF cannot be attributed to systemic
changes.
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Table 2. Baseline, pre-glucose and postprandial adipose tissue
blood flow (ATBF) in response to ACE inhibition (enalaprilate)
and AT1 receptor blockade (losartan)
Baseline Pre-glucose Postprandial
ACE inhibition 4.6 ± 0.9 5.3 ± 1.1 7.1 ± 1.1∗
Control 5.0 ± 1.1 4.9 ± 1.1 7.0 ± 1.5∗
AT1 receptor blockade 3.6 ± 1.1 5.5 ± 1.2†‡ 6.3 ± 1.2†
Control 4.1 ± 1.2 4.1 ± 1.2 6.2 ± 1.5†
Control indicates infusion of saline on the contralateral site
in the same individual. The effect of ACE inhibition and AT1
receptor blockade on fasting adipose tissue blood flow (ATBF)
was examined by comparison of ATBF during the pre-glucose
period with baseline ATBF. The effect of treatments on post-
prandial ATBF (ingestion of an oral glucose load) was assessed
by comparison with baseline ATBF. Data are presented as
mean ± S.E.M., in ml (100 g tissue)−1 min−1. ∗P < 0.05 versus
baseline; †P < 0.01 versus baseline; ‡P < 0.01 versus control.
Effects of AT1 receptor blockade
and ACE inhibition on ATBF
At the saline infusion (control) sites, ATBF was stable
during the baseline period and the 30 min period before
glucose ingestion (pre-glucose period) in the ACE
inhibition experiment (baseline: 5.0 ± 1.1; pre-glucose:
4.9 ± 1.1 ml (100 g tissue)−1 min−1, not significant (n.s.))
and the AT1 receptor blockade experiment (baseline:
4.1 ± 1.2; pre-glucose: 4.1 ± 1.2 ml (100 g tissue)−1
min−1, n.s.) (Table 2). There were no significant
differences in baseline ATBF between contralateral saline
and treatment sites (all saline during baseline period). In
response to glucose ingestion, the ATBF increase on the
control (saline infusion) site was comparable in the ACE
inhibition (42%, P < 0.01) and AT1 receptor blockade
(50%, P < 0.01) experiments (Figs 3 and 4 and Table 2).
Figure 2. ATBF in response to local stimulation
with Ang II
Ang II was applied at three concentrations: 10−9 M,
10−7 M and 10−5 M (•) (n = 4). , microinfusion of
saline (control). Values are means ± S.E.M.
Fasting ATBF was not affected by local ACE
inhibition (baseline: 4.6 ± 0.9; pre-glucose: 5.3 ± 1.1 ml
(100 g tissue)−1 min−1, n.s.) (Fig. 3), but was increased
by 53% during local AT1 receptor blockade (baseline:
3.6 ± 1.1; pre-glucose: 5.5 ± 1.2 ml (100 g tissue)−1
min−1, P < 0.01) (Fig. 4 and Table 2).
Local ACE inhibition and AT1 receptor blockade
did not affect the postprandial enhancement of ATBF.
The ATBF increase after glucose ingestion during ACE
inhibition (baseline: 4.6 ± 0.9; postprandial: 7.1 ± 1.1 ml
(100 g tissue)−1 min−1, P = 0.02) was not significantly
different compared to the ATBF increase at the saline
control site (baseline: 5.0 ± 1.1; postprandial: 7.0 ± 1.5 ml
(100 g tissue)−1 min−1, P = 0.02). Likewise, the ATBF
increase after the oral glucose load during AT1 receptor
blockade (baseline: 3.6 ± 1.1; postprandial: 6.3 ± 1.2 ml
(100 g tissue)−1 min−1, P < 0.01) was comparable with
the ATBF increase at the saline control site (baseline:
4.1 ± 1.2; postprandial: 6.2 ± 1.5 ml (100 g tissue)−1
min−1, P < 0.01). This is further illustrated by comparable
ATBF AUCs during local ACE inhibition (ACE inhibition:
5.8 ± 0.9; control: 5.8 ± 0.2 ml (100 g tissue)−1 min−1,
n.s.) and AT1 receptor blockade (AT1 receptor blockade:
5.3 ± 1.1; control: 4.9 ± 1.3 ml (100 g tissue)−1 min−1,
n.s.) compared to control.
Interaction between Ang II and NO in ATBF regulation
No significant differences in baseline ATBF were observed
between control and treatment sites (all saline during
baseline period). NOS blockade by l-NMMA induced a
∼30% decrease in fasting ATBF at both NOS blockade
sites (t0 to t60) (both P = 0.001) (Fig. 5). At t60, one
of the saline sites was switched to the AT1 receptor
blocker losartan and one of the NOS blockade sites was
C© 2006 The Authors. Journal compilation C© 2006 The Physiological Society
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Figure 3. ATBF in response to local ACE
inhibition
•, pharmacological inhibition of Ang II
production by the ACE inhibitor enalaprilate
(10−3 M) (n = 6). , contralateral saline control.
Oral glucose is given at t60 to stimulate ATBF.
Values are means ± S.E.M.
switched to the NOS blocker l-NMMA in combination
with the AT1 receptor blocker. Local AT1 receptor blockade
increased fasting ATBF compared to contralateral saline
infusion (60% versus 6%, P = 0.001, respectively), whereas
combined AT1 receptor and NOS blockade elevated fasting
ATBF compared to NOS blockade alone (39% versus
−7%, P = 0.003, respectively). AT1 receptor blockade
induced a more pronounced increase in ATBF compared
to combined AT1 receptor and NOS blockade (60% versus
39%, P = 0.02, respectively). However, after correction for
corresponding changes in ATBF at the control sites, the
net increase in ATBF during local AT1 receptor blockade
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Figure 4. ATBF in response to local AT1
receptor blockade
•, pharmacological blockade of the AT1
receptor by losartan (10−3 M) (n = 6).
, contralateral saline control. Oral glucose is
given at t60 to stimulate ATBF. Values are
means ± S.E.M.
(control: saline site) was not significantly different from the
net increase in ATBF during combined AT1 receptor and
NOS blockade (control: NOS blockade site) (54% versus
46%, respectively).
Discussion
We demonstrated that, using the recently developed
microinfusion technique, Ang II acts as a potent vaso-
constrictor in adipose tissue under fasting conditions, as
shown by the marked decrease in ATBF when Ang II was
C© 2006 The Authors. Journal compilation C© 2006 The Physiological Society
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infused locally. Local ACE inhibition (inhibition of local
Ang II generation) showed that locally produced Ang II
in adipose tissue does not appear to regulate ATBF, as
no significant change in ATBF was observed. In contrast,
AT1 receptor blockade (blockade of Ang II action) induced
a marked increase in ATBF, indicating that circulating
Ang II that reaches adipose tissue is a major regulator of
fasting ATBF. Ang II does not appear to have great impact
on the postprandial enhancement of ATBF. Finally, the
Ang II–NO interaction experiments demonstrated that a
major proportion of the Ang II-induced decrease of ATBF
is NO independent. Biochemical parameters and blood
pressure were unchanged during the course of the different
experiments, which clearly indicates that there were no
systemic effects of the pharmacological agents that were
locally infused in adipose tissue.
The Ang II dose–response data show that local
administration of Ang II to abdominal subcutaneous
adipose tissue induced a dose-dependent decrease in
fasting ATBF, which was sustained throughout the course
of the experiment. In line with the well-known vaso-
constrictive effect of Ang II in other tissues, this finding
was not unexpected. The magnitude of the observed effect
indicates that Ang II could be a major regulator of fasting
ATBF in humans. These observations are in agreement
with our previous findings, where we showed that Ang II
reduced adipose and skeletal muscle tissue blood flow
under fasting conditions using the microdialysis technique
(Goossens et al. 2004).
There is evidence that Ang II may be produced locally in
adipose tissue (Dzau, 1988; Unger & Gohlke, 1990; Phillips
et al. 1993; Danser, 1996; Harte et al. 2005) and could
play a role in obesity-related hypertension and insulin
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Figure 5. ATBF in response to local AT1
receptor blockade alone and in
combination with NOS blockade
ATBF in response to local AT1 receptor
blockade by losartan (10−3 M) (•), contralateral
saline control for AT1 receptor blockade ( ),
local NOS blockade by L-NMMA (10−3 M) alone
and in combination with AT1 receptor blockade
(10−3 M) (), and local NOS blockade (10−3 M)
(control for AT1 receptor blockade in
combination with NOS blockade) () (n = 5).
Values are means ± S.E.M.
resistance (Goossens et al. 2003). It is not easy to investigate
the actions of Ang II in individual tissues, but an elegant
approach to examining such a question has recently been
made using a cross-transplantation strategy and AT1A
receptor-deficient mice. The equal contribution of Ang II
actions in the kidney and in extrarenal tissues with regard
to blood pressure regulation by the renin–angiotensin
system (RAS) was demonstrated (Crowley et al. 2005).
In addition, it is extremely difficult to disentangle the
physiological relevance of locally produced and circulating
Ang II in an individual tissue. With the model used in the
present study, we are to our knowledge the first to
determine the relative contributions of locally produced
Ang II in adipose tissue and circulating Ang II that reaches
adipose tissue to an Ang II-induced effect in this tissue,
in this case the Ang II-induced effect on ATBF. To achieve
this, we exposed the adipose tissue to selective AT1 receptor
blockade and ACE inhibition. For reasons related to the
methodology used, it was impossible to demonstrate
that local Ang II production was indeed decreased after
local ACE inhibition. However, it seems highly likely that
substantial inhibition of local Ang II production was
accomplished by local ACE inhibition, as > 95% blockade
of Ang I-to-Ang II conversion has been demonstrated in
the human forearm using the same ACE inhibitor and
an even lower dose than was used in the present study
(Saris et al. 2000). Similarly, a high dose of the AT1
receptor blocker was administered to substantially block
Ang II action. We demonstrated that local AT1 receptor
blockade markedly increased fasting ATBF, whereas fasting
ATBF was not significantly increased during local ACE
inhibition, suggesting that fasting ATBF is predominantly
controlled by circulating Ang II concentrations, whereas
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locally produced Ang II does not appear to regulate ATBF.
Because Ang II is produced by the adipocyte, the present
data suggest that locally produced Ang II in adipose tissue
acts as a paracrine hormone that does not reach the
endothelium to induce vasoconstriction.
We cannot fully exclude the possibility that locally
generated Ang II plays a minor role in ATBF regulation,
because ACE-independent pathways of Ang II generation
have been demonstrated in several tissues (Urata et al.
1996; Wolny et al. 1997; Hollenberg et al. 1998), and human
studies indicate that such pathways could substantially
contribute to total Ang II formation (Hollenberg, 2002).
However, there is no evidence that non-ACE pathways
play a role in Ang II formation in vivo in human adipose
tissue. Secondly, ACE inhibition reduces the breakdown of
bradykinin (Linz et al. 1995; Waeber & Brunner, 1996), and
in vitro findings and animal studies suggest that this may
lead to a vasodilatory response via the cGMP/NO pathway
(Gohlke et al. 1998; Siragy & Carey, 1999; Tsutsumi
et al. 1999). Based on the present findings, however,
involvement of ACE inhibitor-induced stimulation of the
bradykinin/cGMP/NO pathway in ATBF regulation seems
unlikely.
There were several reasons why we wanted to address
the question as to whether the Ang II-induced decrease in
ATBF is dependent on interaction with NO. First, it has
been demonstrated that NOS inhibition decreased fasting
ATBF (Ardilouze et al. 2004a), suggesting that the balance
between Ang II and NO stimulation may be an important
determinant of the vascular tone and thus ATBF under
fasting conditions. Secondly, it can be argued that the
increase in ATBF during AT1 receptor blockade may be
enhanced by increased production of NO. In this case, AT1
receptor blockade may increase Ang II action through the
Ang II type 2 (AT2) receptor, and it has been suggested that
this receptor may play a counter-regulatory role mediated
via bradykinin and NOS against the pressor actions of
Ang II (Gohlke et al. 1998; Siragy & Carey, 1999; Tsutsumi
et al. 1999). Furthermore, Ang II increased through its AT1
receptor the activity of the superoxide-producing enzyme
NADPH oxidase and thereby inactivated NO, leading
to impaired endothelium-dependent vasodilatation (de
Gasparo, 2002). In line with this, there is evidence for
increased NO bioavailability and decreased oxidative
stress after AT1 receptor blockade (de Gasparo, 2002).
Therefore, both stimulation of the AT2 receptor, resulting
in stimulation of the bradykinin/cGMP/NO pathway,
and increased NO action due to inhibition of NADPH
oxidase activity could be relevant in (pathophysiological)
situations where AT1 receptor blockers are used. Our
Ang II–NO interaction experiments clearly show that the
major proportion of the increase in ATBF during AT1
receptor blockade is NO independent or, in other words,
that the Ang II-induced decrease in ATBF is predominantly
independent of NO action.
The postprandial enhancement of ATBF was not
affected by either ACE inhibition or AT1 receptor blockade,
suggesting that Ang II has no major effect on the regulation
of ATBF after a meal. This is in accordance with
previous investigations showing that postprandial ATBF
is principally controlled by the β-adrenergic system
(Simonsen et al. 1990; Ardilouze et al. 2004a). The
ATBF response induced by a meal may have metabolic
consequences. It has been shown that the extraction of
plasma triacylglycerol is elevated with increasing ATBF
(Samra et al. 1996b), and this may also be the case for
glucose extraction. The present data show that Ang II is
involved in fasting, but not postprandial ATBF regulation.
However, because Ang II decreases the absolute level of
fasting ATBF, this may result in a reduced absolute ATBF
after a meal in conditions where RAS activity is increased.
This could have pathophysiological implications in that
postprandial hyperlipidaemia and hyperglycaemia may
occur, which are well-known cardiovascular risk factors.
In conclusion, the present findings demonstrate that
circulating Ang II is a major regulator of fasting ATBF, and
that a major proportion of the Ang II-induced decrease of
ATBF is NO independent. Locally produced Ang II does
not appear to regulate ATBF. Furthermore, Ang II appears
to have no major effect on the postprandial enhancement
of ATBF.
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